Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Vaccine ; 25(13): 2366-74, 2007 Mar 22.
Article in English | MEDLINE | ID: mdl-17069936

ABSTRACT

For over a half of a century, Native American populations have participated in numerous studies regarding the epidemiology, prevention and treatment of infectious diseases. These studies have resulted in measures to prevent morbidity and mortality from many infectious diseases. The lessons learned from these studies and their resultant prevention or treatment interventions have been applied around the world, and have had a major impact in the reduction of global childhood morbidity and mortality.


Subject(s)
Indians, North American , Infection Control/methods , Humans
2.
Am J Epidemiol ; 160(3): 270-8, 2004 Aug 01.
Article in English | MEDLINE | ID: mdl-15258000

ABSTRACT

Streptococcus pneumoniae is the most common cause of invasive bacterial disease among children worldwide. The authors aimed to determine the incidence, clinical characteristics, and serotype distribution of invasive pneumococcal disease (IPD) among Navajo children in the southwestern United States. Active population-based laboratory surveillance for IPD among resident members of the Navajo Nation under 18 years of age was conducted between 1989 and 1996. During this 8-year period, 706 cases of IPD were identified. The rate of disease varied by age, with the highest rate being observed among children aged 6-11 months (727 cases/100,000 person-years), followed by children aged 0-11 months, 0-23 months, and 0-59 months (568, 537, and 272 cases/100,000 person-years, respectively). Among children aged 0-23 months, 60.3% of cases were caused by serotypes in the seven-valent conjugate pneumococcal vaccine (71.5% from 1989-1993 and 58.3% from 1994-1996). Navajo children are at increased risk of IPD in comparison with the general US population. The distribution of disease-causing serotypes is similar to that of many countries in the developing world. Prevention strategies should include the use of licensed pneumococcal protein conjugate vaccine; however, a substantial proportion of disease is caused by nonvaccine serotypes. These data are critical for assessing the impact of these vaccines in this high-risk population.


Subject(s)
Indians, North American/statistics & numerical data , Pneumococcal Infections/ethnology , Age Distribution , Arizona/epidemiology , Child, Preschool , Female , Humans , Incidence , Infant , Infant, Newborn , Male , New Mexico/epidemiology , Pneumococcal Infections/microbiology , Pneumococcal Infections/mortality , Pneumococcal Vaccines , Population Surveillance , Seasons , Serotyping/statistics & numerical data , Sex Distribution , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/isolation & purification , Survival Analysis , Utah/epidemiology , Vaccines, Conjugate
3.
Vaccine ; 22(9-10): 1260-4, 2004 Mar 12.
Article in English | MEDLINE | ID: mdl-15003655

ABSTRACT

We evaluated the safety and immunogenicity of two octavalent pneumococcal polysaccharide vaccines (serotypes 3, 4, 6B, 9V, 14, 18C, 19F, and 23F) conjugated to either diphtheria toxoid (PncD) or tetanus protein (PncT) among White Mountain Apache and Gila River Indian Community infants. This was a prospective, non-randomized, open label, comparative pilot study of PncD and PncT. Since this was a pilot study, a small sample size of 60 infants was enrolled. Enrolled healthy infants received either PncD or PncT at 2, 4, and 6 months of age. Antibody concentrations were measured by enzyme-immunoassay (EIA) prior to each dose and 1 month after the last dose. Local reaction rates were similar between PncD and PncT groups. The geometric mean concentrations (GMCs) were significantly higher for PncD than PncT for serotype 3 whereas GMCs were significantly higher for PncT for serotype 4. For this pilot study, both vaccines appeared to be safe and immunogenic in this group of American Indian infants.


Subject(s)
Pneumococcal Infections/immunology , Pneumococcal Vaccines/adverse effects , Pneumococcal Vaccines/immunology , Adjuvants, Immunologic/pharmacology , Antibodies, Bacterial/analysis , Antibodies, Bacterial/biosynthesis , Diphtheria Toxoid/pharmacology , Erythema/etiology , Erythema/pathology , Female , Humans , Indians, North American , Infant , Male , Pilot Projects , Pneumococcal Infections/prevention & control , Serotyping , Tetanus Toxin/pharmacology , Vaccines, Conjugate/immunology
4.
J Clin Microbiol ; 41(6): 2401-7, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12791856

ABSTRACT

Helicobacter pylori is chiefly acquired in childhood, but the exact timing of acquisition is not well understood. The main goal of this study was to assess H. pylori acquisition in a pediatric population. We studied two cohorts of Native American children: a birth cohort of 50 children and 58 older children (mean age, 53 months). We measured serum immunoglobulin G (IgG), IgM, and IgA antibodies to H. pylori whole-cell antigen and IgG antibodies to CagA. Among 44 birth cohort children monitored for more than 12 months, 24 (54.5%) had seroconversions, 7 (15.9%) were transient, and 17 (38.6%) were persistent. Among the older children, 49 (84.5%) of the 58 children were monitored for 1 year; 34 (69.4%) had H. pylori antibodies at study entry. During the next year, 7 (20.6%) children seroreverted, and of 15 initially negative children, 5 (33.3%) seroconverted. In both groups, evaluation of CagA antibodies increased the sensitivity of H. pylori detection. Serum pepsinogen I (PGI) levels in H. pylori-negative children rose significantly until age 6 months and remained constant for the next 19 months. At the time of H. pylori seroconversion, PGI peaked to levels significantly higher than in the never-seroconverted (P = 0.02) and the pre-seroconverted (P = 0.03) children, but then declined to levels paralleling those of H. pylori-negative children. Thus, H. pylori acquisition, accompanied by a transient PGI increase, was frequent in this population, especially in the second and third years of life, but often was brief.


Subject(s)
Antibodies, Bacterial/blood , Helicobacter Infections/epidemiology , Helicobacter pylori/immunology , Indians, North American , Adult , Antigens, Bacterial/immunology , Bacterial Proteins/immunology , Child , Child, Preschool , Female , Helicobacter Infections/microbiology , Humans , Infant , Pepsinogen A/blood
5.
Pediatrics ; 110(2 Pt 1): e20, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12165619

ABSTRACT

OBJECTIVE: The hospitalization rate for bronchiolitis of any cause among US children younger than 1 year is estimated at 31.2 per 1000. No data exist on respiratory syncytial virus (RSV)-specific hospitalization rates among high-risk Native Americans other than Alaska Natives, for whom the incidence of RSV hospitalization was estimated at 150 per 1000 among infants younger than 1 year. We aimed to estimate RSV hospitalization rates among Navajo and White Mountain Apache children younger than 2 years. METHODS: We conducted prospective population-level hospital-based surveillance to determine RSV hospitalization rates among Navajo and White Mountain Apache children younger than 2 years. From 1997 to 2000, all children who were admitted for acute lower respiratory tract infection between October 1 and March 31 had a nasopharyngeal aspirate obtained and tested for RSV by commercial enzyme immunoassay kits. We reviewed charts of children who tested positive for RSV antigen to determine disease severity. RESULTS: During 3 RSV seasons (1997-2000), 51.3% of 1837 admissions for acute lower respiratory tract infection among children younger than 2 years were attributed to RSV infection. The overall seasonal RSV hospitalization rate among children younger than 2 years was 63.6 per 1000 and 91.3 per 1000 among children younger than 1 year. In a univariate analysis, predictors of severity included age <6 months (relative risk: 6.8; 95% confidence interval: 3.1-17.0). CONCLUSIONS: Navajo and White Mountain Apache children are at high risk for RSV disease requiring hospitalization. A lower threshold for hospitalization or underlying chronic conditions that predispose to severe RSV disease do not seem to explain high RSV hospitalization rates in this population.


Subject(s)
Indians, North American/statistics & numerical data , Respiratory Syncytial Virus Infections/epidemiology , Hospitalization/statistics & numerical data , Humans , Infant , Logistic Models , Population Surveillance , Prospective Studies , Respiratory Syncytial Virus Infections/ethnology , Risk Factors , Severity of Illness Index , United States/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...